A new treatment approach based on nanotechnology was found effective in mouse models for the most common type of lung cancer, non-small cell lung cancer (NSCLC). The disease continues to be difficult to treat, with five-year survival rates of about 36 percent for stage 3A tumors. Findings of the study were published in the journal iMolecular Pharmaceutics/i.
The nanoparticles were designed to deliver a molecule that's been shown to stall tumor growth and may make tumors more susceptible to chemotherapy....
A new treatment approach based on nanotechnology was found effective in mouse models for the most common type of lung cancer, non-small cell lung cancer (NSCLC). The disease continues to be difficult to treat, with five-year survival rates of about 36 percent for stage 3A tumors. Findings of the study were published in the journal iMolecular Pharmaceutics/i.
The nanoparticles were designed to deliver a molecule that's been shown to stall tumor growth and may make tumors more susceptible to chemotherapy....